Sept. 16, 2008 - MannKind Corporation (Nasdaq: MNKD) released preliminary top-line results from a Phase 3 clinical study of the Technosphere(R) Insulin System in patients with type 1 diabetes (Study 009). This study compared the safety and efficacy of prandial inhalations of Technosphere Insulin (the TI group) versus prandial subcutaneous injections of insulin aspart (the comparator group). Both groups also received daily subcutaneous injections of a basal insulin (insulin glargine). Study Highlights
Technosphere Insulin, compared to a rapid-acting insulin analog, showed:
- Comparable reductions in A1C levels
- Comparable numbers of patients reaching pre-defined A1C goals
- Superior fasting blood glucose levels
- Better early post-prandial glucose control
- Fewer patients experiencing hypoglycemic events
- Weight loss versus weight gain
- No adverse effects on pulmonary function... MannKind's Press Release -
